ATAI Life Sciences NV
F:9VC
ATAI Life Sciences NV
F:9VC
Price:
3.06
EUR
-4.38%
Market Cap:
€512.3m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
ATAI Life Sciences NV
F:9VC
|
DE |
|
Ekso Bionics Holdings Inc
NASDAQ:EKSO
|
US |
|
T
|
TCL Electronics Holdings Ltd
OTC:TCLHF
|
CN |
|
S
|
SK Hynix Inc
SWB:HY9H
|
KR |
|
A
|
Abbott Laboratories
SWB:ABL
|
US |
|
I
|
Intuit Inc
F:ITU
|
US |
|
C
|
Cardinal Health Inc
F:CLH
|
US |
|
I
|
Industria de Diseno Textil SA
MIL:ITX
|
ES |
|
T
|
Tesco PLC
OTC:TSCDY
|
UK |
Wall St Price Targets
9VC Price Targets Summary
ATAI Life Sciences NV
ATAI Life Sciences NV
Wall Street analysts forecast 9VC stock price to rise over the next 12 months.
According to Wall Street analysts, the average 1-year price target for 9VC is 10.49 EUR with a low forecast of 5.23 EUR and a high forecast of 19.4 EUR.
Lowest Forecast
Price Target
5.23
EUR
71% Upside
Average Forecast
Price Target
10.49
EUR
243% Upside
Highest Forecast
Price Target
19.4
EUR
534% Upside
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 9VC's stock price target?
Price Target
10.49
EUR
10.49
EUR
According to Wall Street analysts, the average 1-year price target for 9VC is 10.49 EUR with a low forecast of 5.23 EUR and a high forecast of 19.4 EUR.
What is the Revenue forecast for ATAI Life Sciences NV?
Projected CAGR
125%
125%
The compound annual growth rate for Revenue over the next 8 years is 125%.
